NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed an agreement with preferred provider organization Prime Health Services to offer its ConfirmMDx for Prostate Cancer test to Prime Health's members.

MDxHealth said the agreement covers all 50 states and extends ConfirmMDx's testing to around 144 million covered lives throughout the US. Prime Health serves more than 700,000 providers and facilities nationwide through its Prime Health Delivery System.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.